Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

667 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ixekizumab im Vergleich zu Fumarsäureestern und Methotrexat bei der Behandlung der Nagelpsoriasis bei Patienten mit mittelschwerer bis schwerer Psoriasis: Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate-to-severe psoriasis.
Augustin M, Mrowietz U, Willsmann-Theis D, Gerdes S, Fotiou K, Schuster C, Mert C, Holzkaemper T, Behrens F, Pinter A. Augustin M, et al. Among authors: pinter a. J Dtsch Dermatol Ges. 2024 Feb;22(2):278-282. doi: 10.1111/ddg.15292_g. J Dtsch Dermatol Ges. 2024. PMID: 38361190 No abstract available.
A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment.
Reich K, Augustin M, Thaçi D, Pinter A, Leutz A, Henneges C, Schneider E, Schacht A, Dossenbach M, Mrowietz U. Reich K, et al. Among authors: pinter a. Br J Dermatol. 2020 Apr;182(4):869-879. doi: 10.1111/bjd.18384. Epub 2019 Nov 19. Br J Dermatol. 2020. PMID: 31376153 Free PMC article. Clinical Trial.
Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
Thaçi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A, Eyerich K. Thaçi D, et al. Among authors: pinter a. Br J Dermatol. 2020 Aug;183(2):265-275. doi: 10.1111/bjd.18696. Epub 2020 Jan 20. Br J Dermatol. 2020. PMID: 31705526 Clinical Trial.
Measuring Quality of Life in Hidradenitis Suppurativa: Development and Validation of a Disease-specific Patient-reported Outcome Measure for Practice and Research.
Otten M, Augustin M, Blome C, Topp J, Niklaus M, Hilbring C, Bechara FG, Pinter A, Zouboulis CC, Anzengruber F, Kirsten N. Otten M, et al. Among authors: pinter a. Acta Derm Venereol. 2023 Jan 31;103:adv00859. doi: 10.2340/actadv.v102.2485. Acta Derm Venereol. 2023. PMID: 36129249 Free PMC article.
667 results